CD47, also known as integrin-associated protein (IAP) or thrombospondin receptor, is a transmembrane glycoprotein expressed on the surface of cells throughout the body, including neurons, glial cells, and immune cells. The protein functions as a critical "don't eat me" signal that regulates interactions between cells and phagocytes—immune cells responsible for engulfing and destroying pathogens and debris. CD47 is encoded by the CD47 gene located on human chromosome 3q13.1. The protein comprises an extracellular immunoglobulin V-like domain, a transmembrane domain, and a cytoplasmic tail with multiple functional regions. In the context of neurodegeneration, CD47 plays an increasingly recognized role in modulating neuroinflammation, microglial activation, and the clearance of neuronal debris—processes that are fundamentally altered in diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
Function and Biology
...
CD47 Protein
Overview
CD47, also known as integrin-associated protein (IAP) or thrombospondin receptor, is a transmembrane glycoprotein expressed on the surface of cells throughout the body, including neurons, glial cells, and immune cells. The protein functions as a critical "don't eat me" signal that regulates interactions between cells and phagocytes—immune cells responsible for engulfing and destroying pathogens and debris. CD47 is encoded by the CD47 gene located on human chromosome 3q13.1. The protein comprises an extracellular immunoglobulin V-like domain, a transmembrane domain, and a cytoplasmic tail with multiple functional regions. In the context of neurodegeneration, CD47 plays an increasingly recognized role in modulating neuroinflammation, microglial activation, and the clearance of neuronal debris—processes that are fundamentally altered in diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
Function and Biology
CD47 functions primarily as a ligand for signal regulatory protein alpha (SIRPα) on myeloid cells, including macrophages and microglia. This interaction delivers inhibitory signals that suppress phagocytic activity. Additionally, CD47 serves as a ligand for thrombospondin (TSP-1), a matricellular protein involved in immune regulation and tissue remodeling. The CD47-TSP-1 interaction modulates integrin-mediated cell adhesion and migration. Under normal physiological conditions, CD47 expression on healthy neurons and glia helps protect these cells from unwanted phagocytic elimination. The protein is particularly important in the central nervous system, where microglia—resident immune cells derived from yolk sac precursors—constantly survey neural tissue for damaged or dead cells. Appropriate CD47 signaling maintains the balance between necessary clearance of genuinely damaged neurons and inappropriate destruction of viable neural tissue.
Role in Neurodegeneration
Dysregulation of CD47 signaling contributes to several neurodegenerative diseases through two contrasting mechanisms. In some conditions, reduced CD47 expression on neurons or excessive microglial SIRPα signaling leads to excessive phagocytosis of viable neurons. In Alzheimer's disease, recent research indicates that dysregulated CD47-SIRPα interactions contribute to inappropriate microglial-mediated synapse elimination, accelerating cognitive decline. Conversely, in other contexts, aberrantly elevated CD47 expression may prevent clearance of pathological debris, including amyloid-beta aggregates and phosphorylated tau, perpetuating neuroinflammation. In Parkinson's disease, impaired CD47 signaling on dopaminergic neurons may enhance their vulnerability to microglial attack, particularly when combined with alpha-synuclein pathology. In ALS, altered CD47 expression on motor neurons correlates with disease progression, and therapeutic modulation of CD47-SIRPα signaling shows promise in preclinical models.
Molecular Mechanisms
CD47-mediated neuroprotection operates through SIRPα-dependent and SIRPα-independent mechanisms. SIRPα engagement recruits protein tyrosine phosphatase SHP-1 to the microglial cell membrane, which dephosphorylates downstream signaling molecules and suppresses pro-inflammatory cytokine production, including TNF-α, IL-6, and IL-1β. This pathway also reduces reactive oxygen species generation and prevents microglial activation. CD47-TSP-1 interactions modulate integrin signaling, affecting cell migration and inflammatory responses. In the diseased brain, aberrant CD47 signaling interacts with other immune checkpoints, including PD-1/PD-L1 and CD200/CD200R pathways, creating a complex regulatory landscape. Genetic polymorphisms in CD47 and variations in CD47 expression influenced by aging, neuroinflammation, and disease-specific pathology alter these regulatory mechanisms.
Clinical and Research Significance
CD47-targeted therapeutics represent an emerging therapeutic frontier in neurodegeneration. Strategies include enhancing CD47 expression on vulnerable neurons, blocking CD47 to promote clearance of pathological debris, and modulating SIRPα signaling in microglia. Preclinical studies demonstrate that CD47-Fc fusion proteins protect neurons in ALS models, while CD47-blocking approaches enhance amyloid clearance in Alzheimer's models. Clinical trials investigating CD47-modulating therapies in neurodegeneration are in early phases.